Basides, experimental animal studies on thoracic tumors have shown that S-1 not only inhibits tumor growth, but also initiates a favorable tumor microenvironment, increasing the efficacy of its combined use with immune checkpoint inhibitors (13). Here, PSMD1 is linked to neoplasm.